STXS NYSE Electromedical & Electrotherapeutic Apparatus Financials FY2016βFY2025
Stereotaxis, Inc. had $32.4M of revenue in fiscal 2025, up 20.3% on the year before. Over five years, revenue changed +4.0% a year on average.
Last close Β· Oct 23, 2026
$1.02
2.2%Hi! I read Stereotaxis, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+20.3%
Yes. Sales grew 20.3% last year.
Does it make a profit?
β66.8%
No. It lost money last year.
Does profit turn into cash?
β42.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Stereotaxis, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 10, 2026
Tuesday Β· in 15 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 11, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 12, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 9, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 11, 2025 | Q3 '25 | Time not announced | 8-K β |
| Jul 17, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 12, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 3, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 12, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Stereotaxis, Inc. had $32.4M of revenue in fiscal 2025, up 20.3% on the year before. Over five years, revenue changed +4.0% a year on average. Its operating margin was β68.3%, up 23.6Β pts: of every 100 in sales, about β68 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Stereotaxis, Inc. lost $21.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$13.8M in fiscal 2025, β42.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Stereotaxis, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 6.8%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Stereotaxis, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $38.7M | $28.4M | $19.8M | $12.2M | $13.4M |
| Current ratio | 3.9x | 3.0x | 2.5x | 1.2x | 1.5x |
| Quick ratio | 3.5x | 2.5x | 1.9x | 0.8x | 1.1x |
| Total assets | $61.0M | $53.4M | $41.9M | $46.7M | $52.3M |
| Total liabilities | $21.6M | $21.5M | $20.0M | $35.3M | $33.5M |
| Shareholders' equity | $33.8M | $26.3M | $16.3M | $6.1M | $13.5M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Stereotaxis, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 4 / 8 | 1 / 8 | 2 / 8 | 2 / 8 | 1 / 8 | 2 / 8 | 1 / 8 | 4 / 8 |
| Accruals ratio | 6.1% | β7.7% | 18.3% | 0.1% | β6.3% | β13.3% | β17.3% | β24.3% | β35.1% | β16.1% |
| Altman Z'' | β81.04 | β162.89 | β81.95 | β31.14 | β22.48 | β22.33 | β29.07 | β41.33 | β41.89 | β37.38 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $32.2M | $31.1M | $29.3M | $28.9M | $26.6M | $35.0M | $28.1M | $26.8M | $26.9M | $32.4M |
| Net interest income | β | β | β$0.0M | $0.2M | $0.1M | β$0.0M | $0.5M | $1.1M | $0.7M | $0.5M |
| Gross profit | $24.6M | $20.4M | $23.6M | $22.8M | $19.0M | $23.2M | $18.5M | $14.9M | $14.6M | $17.1M |
| Research and development | $5.5M | $6.7M | $8.2M | $9.0M | $8.1M | $10.2M | $10.6M | $10.3M | $9.8M | $9.4M |
| Operating income | β$6.4M | β$5.9M | β$2.5M | β$4.8M | β$6.7M | β$12.9M | β$18.8M | β$21.8M | β$24.7M | β$22.1M |
| Interest expense | $2.5M | $0.2M | $0.0M | β | β | β | β | β | β | β |
| Net income | β$5.3M | β$5.9M | $0.1M | β$4.6M | β$6.6M | β$10.7M | β$18.3M | β$20.7M | β$24.0M | β$21.6M |
| Net income to common | β$11.8M | β$7.3M | β$1.3M | β$6.0M | β$8.0M | β$12.1M | β$19.6M | β$22.1M | β$25.4M | β$22.9M |
| Diluted EPS | β$0.54 | β$0.32 | β$0.03 | β$0.10 | β$0.11 | β$0.16 | β$0.26 | β$0.27 | β$0.30 | β$0.25 |
| Diluted shares | 0.02B | 0.02B | 0.05B | 0.06B | 0.07B | 0.08B | 0.08B | 0.08B | 0.09B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$6.6M | β$4.7M | β$2.5M | β$4.6M | β$3.5M | β$2.9M | β$8.4M | β$9.1M | β$8.5M | β$13.7M |
| Capital expenditure | $0.4M | $0.1M | $0.3M | $0.0M | $0.1M | $1.4M | $2.4M | $0.4M | $0.0M | $0.1M |
| Free cash flow | β$7.0M | β$4.8M | β$2.8M | β$4.6M | β$3.6M | β$4.3M | β$10.8M | β$9.5M | β$8.5M | β$13.8M |
| Depreciation and amortization | $0.4M | $0.6M | $0.5M | $0.1M | $0.1M | $0.1M | $0.4M | $0.6M | $0.6M | $0.6M |
| Stock-based compensation | $1.4M | $0.8M | $0.6M | $1.3M | $3.2M | $9.4M | $10.6M | $10.6M | $10.3M | $9.9M |
| Dividends paid | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $8.5M | $3.7M | $10.8M | $30.2M | $43.9M | $38.7M | $28.4M | $19.8M | $12.2M | $13.4M |
| Total debt | β | β | β | β | $2.2M | β | β | β | β | β |
| Current assets | $19.4M | $9.9M | $18.0M | $38.8M | $52.7M | $51.4M | $43.2M | $33.3M | $26.4M | $33.8M |
| Current liabilities | $35.7M | $30.1M | $10.2M | $12.2M | $13.6M | $13.3M | $14.3M | $13.2M | $21.6M | $22.4M |
| Inventory | $5.4M | $1.1M | $1.2M | $1.8M | $3.3M | $4.4M | $7.9M | $8.4M | $8.3M | $9.6M |
| Property and equipment, net | $1.1M | $0.6M | $0.3M | $0.3M | $0.2M | $2.6M | $3.8M | $3.3M | $3.6M | $3.0M |
| Goodwill | β | β | β | β | β | β | β | β | $3.8M | $3.8M |
| Intangible assets | $0.4M | $0.2M | β | β | β | β | β | β | $7.4M | $6.4M |
| Total assets | $21.0M | $10.7M | $18.5M | $43.6M | $55.5M | $61.0M | $53.4M | $41.9M | $46.7M | $52.3M |
| Total liabilities | $36.5M | $31.3M | $11.2M | $15.1M | $15.2M | $21.6M | $21.5M | $20.0M | $35.3M | $33.5M |
| Preferred stock | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β |
| Shareholders' equity | β$21.5M | β$26.6M | $1.3M | $22.8M | $34.6M | $33.8M | $26.3M | $16.3M | $6.1M | $13.5M |
| Margins | ||||||||||
| Gross margin | 76.6% | 65.5% | 80.5% | 78.8% | 71.2% | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% |
| Operating margin | β20.0% | β19.0% | β8.4% | β16.7% | β25.2% | β36.8% | β66.7% | β81.6% | β91.9% | β68.3% |
| EBITDA margin | β18.8% | β17.2% | β6.6% | β16.3% | β24.7% | β36.5% | β65.2% | β79.4% | β89.7% | β66.4% |
| Net margin | β16.4% | β18.9% | 0.4% | β15.9% | β25.0% | β30.6% | β65.0% | β77.4% | β89.3% | β66.8% |
| FCF margin | β21.7% | β15.3% | β9.6% | β16.1% | β13.5% | β12.4% | β38.3% | β35.5% | β31.7% | β42.6% |
| Net interest share of revenue | β | β | β0.1% | 0.8% | 0.3% | β0.0% | 1.7% | 4.1% | 2.6% | 1.5% |
| Returns | ||||||||||
| Return on capital employed | 43.8% | 30.4% | β29.5% | β15.4% | β16.0% | β27.0% | β48.0% | β76.2% | β98.5% | β74.0% |
| Return on equity | β | β | β | β38.1% | β23.2% | β31.3% | β60.8% | β97.0% | β214.5% | β221.3% |
| Return on assets | β25.2% | β37.2% | 0.8% | β14.8% | β13.4% | β18.4% | β32.0% | β43.5% | β54.3% | β43.7% |
| Return on tangible equity | β | β | β100.5% | β26.4% | β23.2% | β35.6% | β74.5% | β135.0% | β | β696.9% |
| Growth | ||||||||||
| Revenue growth | β | β3.2% | β5.8% | β1.5% | β7.9% | 31.5% | β19.6% | β4.9% | 0.5% | 20.3% |
| Net income growth | β | β | β | β4,030.9% | β | β | β | β | β | β |
| Share count change | β | 3.7% | 130.3% | 21.1% | 15.4% | 3.9% | 0.7% | 6.1% | 5.6% | 6.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.1x | β | β | β | β | β |
| Interest coverage | β2.6x | β32.9x | β148.0x | β | β | β | β | β | β | β |
| Current ratio | 0.5x | 0.3x | 1.8x | 3.2x | 3.9x | 3.9x | 3.0x | 2.5x | 1.2x | 1.5x |
| Quick ratio | 0.4x | 0.3x | 1.6x | 3.0x | 3.6x | 3.5x | 2.5x | 1.9x | 0.8x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.3% | 0.3% | 0.9% | 0.1% | 0.3% | 4.0% | 8.4% | 1.4% | 0.1% | 0.3% |
| Stock comp / revenue | 4.2% | 2.5% | 1.9% | 4.6% | 11.9% | 26.7% | 37.6% | 39.7% | 38.1% | 30.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 4.0 | 1.0 | 2.0 | 2.0 | 1.0 | 2.0 | 1.0 | 4.0 |
| Altman Z'' | β81.0 | β162.9 | β82.0 | β31.1 | β22.5 | β22.3 | β29.1 | β41.3 | β41.9 | β37.4 |
| Accruals ratio | 6.1% | β7.7% | 18.3% | 0.1% | β6.3% | β13.3% | β17.3% | β24.3% | β35.1% | β16.1% |
Source: SEC EDGAR XBRL filings (CIK 0001289340). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
